1263818-07-0

Basic information

• Product Name: methyl 4-acetamido-3-methyl-5-nitrobenzoate
• Synonyms: methyl 4-acetamido-3-methyl-5-nitrobenzoate
• CAS NO: 1263818-07-0
• Molecular Weight: 252.227
• Mol File: 1263818-07-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: methyl 4-acetamido-3-methyl-5-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-acetamido-3-methyl-5-nitrobenzoate(1263818-07-0)
• EPA Substance Registry System: methyl 4-acetamido-3-methyl-5-nitrobenzoate(1263818-07-0)

Safety Data

• Hazardous Substances Data: 1263818-07-0(Hazardous Substances Data)

Upstream product

• 2486-70-6 4-amino 3-methylbenzoic acid 
• 67-56-1 methanol 
• 37901-93-2 4-acetamido-3-methyl-5-nitrobenzoic acid 
• 37901-92-1 4-acetamido-3-methylbenzoic acid 
• 239075-25-3 C₁₁H₁₃NO₃ 
• 18595-14-7 methyl 4-amino-3-methylbenzoate 
• 24078-21-5 methyl 3-methyl-4-nitrobenzoate 
• 3113-71-1 3-methyl-4-nitrobenzoic acid 

Downstream Products

• 668276-44-6 methyl 4-amino-3-methyl-5-nitrobenzoate 
• 668276-43-5 methyl 3,4-diamino-5-methylbenzoate 

Relevant articles and documents

One-dimensional channels encapsulated in supramolecular networks constructed of zinc(II), manganese(II), or nickel(II) atoms with 3-(Carboxymethyl)-2, 7-dimethyl-3H-benzo[d]imidazole-5-carboxylic Acid

Four complexes with supramolecular architectures, namely, MZCA·3H2O (1), [Zn(H2O)6] 2+·[MZCA]2·[H2O]6 (2), [Mn(MZCA)2(H2O)4]·2H2O (3), and [Ni(MZCA)2(H2O)4]·2H2O (4) [MZCA = 3-(carboxymethyl)-2, 7-dimethyl-3H-benzo[d]imidazole-5-carboxylic acid], were synthesized and characterized by elemental analysis, IR spectroscopy, and single-crystal X-ray diffraction. Complexes 1 and 2 display a remarkable 3D network with 1D hydrophilic channels. Complexes 3 and 4 are isostructural and exhibit a 3D structure encapsulating 1D 24-membered ring microporous channels. The UV/Vis and fluorescent spectra were measured to characterize complexes 1-4. The thermal stability of complexes 2-4 were also examined.

PROCESS FOR PREPARING AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS

Disclosed herein is a process for preparing amide-substituted imidazo compounds. In particular, disclosed herein is the process for preparing certain amide-substituted imidazo compounds that are useful for inhibiting indoleamine 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.

N-Phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: Design, synthesis and biological evaluation

The design, synthesis, in vitro and in vivo evaluation of 6-substituted benzimidazole with 1, 4-disubsituted or 1, 5-disubsituted indole derivatives as novel angiotensin II receptor antagonists are outlined. Radioligand binding assays showed that several 6-substituted benzimidazole derivatives displayed high affinities binding to the angiotensin II type 1 receptor at the same order of magnitude to telmisartan. The biological evaluation on spontaneously hypertensive rats showed that 2-[4-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazole-1-yl]methyl]-1H-indol-1-yl]benzoic acid, 1c, could cause significant decrease on MBP in a dose dependent manner. Its maximal response lowered 53 mmHg of MBP at 5 mg/kg and 64 mmHg of MBP at 10 mg/kg after oral administration, and the significant antihypertensive effect lasted beyond 24 h, which was better than both losartan and telmisartan. A study designed to determine acute toxicity showed that 1c had low acute toxicity with no significant changes in the weight and no obvious untoward reactions. The encouraging results make 1c an effective and durable anti-hypertension drug candidate and deserve further investigation for therapeutic application.